Top-News
Mittwoch,
14.12.2016 15:30
von
PR Newswire
| Aufrufe: 210
CEMPRA INC. INVESTOR REMINDER: Hagens Berman Reminds Cempra Investors of Lead Plaintiff Deadline
Ein Arzt berät einen Patienten (Symbolbild).
© TommL / Vetta / Getty Images
https://www.gettyimages.de/
PR Newswire
SAN FRANCISCO, Dec. 14, 2016
SAN FRANCISCO, Dec. 14, 2016 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in Cempra Inc. (NASDAQ: CEMP) of the January 3, 2017 Lead Plaintiff deadline.
If you purchased or otherwise acquired Cempra shares between October 22, 2015 and November 1, 2016 and suffered over $75,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
or contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing CEMP@hbsslaw.com.
Cempra allegedly omitted disclosing to investors that its drug, solithromycin, created significant health risks to users.
On November 2, 2016 the Food and Drug Administration reported that solithromycin may cause a serious rise in liver enzymes and result in hepatotoxicity. This report drove the price of Cempra shares down approximately 60% to close at $7.30 per share that day.
On November 3, 2016 Benzinga quoted a stock analyst who stated: "[w]e had previously argued liver enzyme elevations alone would be a navigable subject matter – but the revelation of a previously-undisclosed instance of definitive solithromycin mediated drug-induced liver injury…now fundamentally challenges this hypothesis."
On December 12, 2016, Cempra's President and CEO (Prabha Fernandes) abruptly retired effective immediately.
"We're evaluating the FDA's material and the results of the FDA's advisory panel meeting in the context of the defendants' public statements about solithromycin," said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Cempra should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email CEMP@hbsslaw.com.
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm's Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cempra-inc-investor-reminder-hagens-berman-reminds-cempra-investors-of-lead-plaintiff-deadline-300377585.html
SOURCE Hagens Berman Sobol Shapiro LLP
Werbung
Mehr Nachrichten zur Melinta Therapeutics Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
